In vivo, dexamethasone (a corticosteroid) was found to partially abrogate anti‐PD1 tumour growth inhibition by impairing peripheral CD8+ T‐cell responses [75], and clinically, a meta‐analysis of 16 trials found a negative association between their use and OS/PFS. The gene discussed is CD8A; the disease is neoplasm.